Search

Relay Therapeutics Inc

Lezárt

SzektorEgészségügy

19.04 1.06

Áttekintés

Árfolyamváltozás megosztása

24 óra

Jelenlegi

Minimum

18.63

Maximum

19.23

Fő mutatók

By Trading Economics

Bevétel

-10M

-84M

Értékesítés

-2.7M

350K

Egy részvényre jutó nyereség

-0.41

Profit margin

-23,916.286

Munkavállalók

202

EBITDA

-10M

-83M

Ajánlások

By TipRanks

Ajánlások

Erős vétel

12 hónapos előrejelzés

+45.34% upside

Osztalékok

By Acuity

Következő eredményjelentés

2026. nov. 5.

Piaci statisztika

By TradingEconomics

Piaci kapitalizáció

-65M

4B

Előző nyitás

17.98

Előző zárás

19.04

Hangulat hírek alapján

By Acuity

50%

50%

143 / 339 Rangsor szerint Healthcare

Relay Therapeutics Inc Chart

A múltbeli teljesítmény nem megbízható mutatója a jövőbeli eredményeknek.

Kapcsolódó hírek

2026. szept. 2. 20:08 UTC

News

Relay Therapeutics will participate in two investor conferences in September 2026. Shares are trading roughly flat since Tuesday's close, below the 20-day moving average.

2026. aug. 31. 20:07 UTC

Relay Therapeutics shares are lower today amid broader market pressures and concerns about inflation following the Jackson Hole Economic Symposium.

2026. aug. 28. 21:51 UTC

Relay Therapeutics Inc is trading higher in after-market hours, rebounding from three consecutive lower sessions. No specific news was identified for this movement.

2026. aug. 27. 22:01 UTC

Relay Therapeutics Inc shares are lower in after-market trading, declining from earlier gains amid broader weakness and three consecutive sessions of losses.

2026. aug. 26. 20:08 UTC

Relay Therapeutics Inc is trading lower today amid broader market declines, influenced by inflation data that exceeded expectations and may impact Federal Reserve policy.

2026. aug. 25. 23:41 UTC

Relay Therapeutics Inc shares are lower in after-market hours, with no specific news identified for the decline. The stock remains above its 20-day moving average.

2026. aug. 24. 19:56 UTC

Social Media

Relay Therapeutics is testing a buy point at $20.79, reflecting ongoing interest. The stock remains higher since Friday's close despite an earlier pullback.

2026. aug. 21. 21:01 UTC

Relay Therapeutics Inc is trading higher in after-market hours, up significantly since Friday's close and above its 20-day moving average.

2026. aug. 20. 20:02 UTC

Correlated Moves

Relay Therapeutics Inc shares are lower today, influenced by a decline in the broader Biotechnology sector and significant market volatility. Trading volume remains unusually high.

2026. aug. 19. 23:01 UTC

Relay Therapeutics Inc is trading higher in after-market hours, positioned near the upper end of its one-month range and above its 20-day moving average.

2026. aug. 18. 22:26 UTC

Relay Therapeutics Inc. shares traded lower after market hours, reflecting broader market pressure from rising bond yields and inflation concerns.

2026. aug. 17. 19:36 UTC

Social Media
News

Relay Therapeutics Inc is trading higher amid a Phase 3 trial for its breast cancer treatment and a $53 million investment from Baker Bros.

2026. aug. 14. 21:51 UTC

Social Media

Relay Therapeutics Inc is gaining in after-market trading, supported by social media discussions and a significant portfolio stake from Perceptive Advisors.

2026. aug. 13. 19:16 UTC

Correlated Moves

Relay Therapeutics Inc is trading lower, reflecting broader declines in the biotechnology sector amid fluctuations and rising initial jobless claims.

2026. aug. 10. 19:56 UTC

News
Social Media

Relay Therapeutics shares are higher after Citizens raised its price target to $26, citing confidence in the company's Phase 3 trials.

2026. aug. 7. 20:06 UTC

News
Correlated Moves
Social Media

Barclays raised its price target on Relay Therapeutics to $30.00, contributing to positive sentiment amid ongoing analyst support following the company's Q2 earnings.

2026. aug. 6. 23:02 UTC

News

Relay Therapeutics shares are lower in after-market hours following disappointing Q2 results, including a net loss of $83.7 million and revenue of $350,000.

2026. aug. 5. 22:26 UTC

Relay Therapeutics Inc. shares advanced in after-market trading, maintaining a position above its 20-day moving average amid broader macroeconomic sentiment.

2026. aug. 4. 19:26 UTC

Correlated Moves

Relay Therapeutics Inc is trading higher during Tuesday's session, continuing its upward trend since Monday's close. Broader market sentiment supports this performance.

2026. aug. 3. 21:01 UTC

Relay Therapeutics Inc shares are lower in after-market trading, continuing a downward trend amid three consecutive sessions of declines and no specific news.

2026. júl. 31. 19:16 UTC

Correlated Moves

Relay Therapeutics Inc shares are lower in Friday's session, reflecting broader declines in the biotech sector amid rising yields and inflation concerns.

2026. júl. 30. 17:36 UTC

Correlated Moves
News

Relay Therapeutics Inc is rising as it advances its PI3Kα inhibitor for breast cancer treatment, drawing renewed interest and nearing IPO levels.

2026. júl. 29. 19:36 UTC

Macro Event

Relay Therapeutics Inc shares are higher Wednesday, supported by increased trading volume and recent Federal Reserve decisions on interest rates.

2026. júl. 28. 18:06 UTC

Relay Therapeutics Inc. shares are lower today amid broader market declines, influenced by significant drops in Asian indices and concerns in the semiconductor sector.

2026. júl. 27. 19:56 UTC

Relay Therapeutics Inc. is trading higher, reaching a peak earlier in the session, despite no specific news driving the increase.

2026. júl. 22. 15:46 UTC

Correlated Moves

Relay Therapeutics shares are lower following first-quarter results, which showed a modest decline. The Russell 2000 Index's decrease may also be influencing performance.

2026. júl. 21. 21:51 UTC

Relay Therapeutics Inc shares are higher in after-market trading, reflecting strong momentum amid renewed interest in technology stocks, particularly those related to AI.

2026. júl. 20. 19:16 UTC

Correlated Moves

Relay Therapeutics Inc. is trading lower amid notable volatility, reflecting broader market declines alongside a drop in the ARK Genomic Revolution ETF.

Társak összehasonlítása

Árváltozás

Relay Therapeutics Inc Előrejelzés

Célár

By TipRanks

45.34% elmozdulás felfelé

12 hónapos előrejelzés

Átlag 27.63 USD  45.34%

Magas 31 USD

Alacsony 20 USD

9 Wall Street elemző 12 hónapos célárain alapulva a(z)Relay Therapeutics Inc termékhez az elmúlt 3 hónapban.

Értékelési konszenzus

By TipRanks

Erős vétel

9 ratings

9

Vétel

0

Tartás

0

Eladás

Hangulat

By Acuity

143 / 339 Rangsor szerint Egészségügy

Hangulat hírek alapján

Neutral

Volatilitás

Átlag alatti

Hírmennyiség (RCV)

Átlag alatti

Pénzügyek

Értékesítési és adminisztrációs költségek

Üzemeltetési költségek

Adózás előtti nyereség

Értékesítés

Értékesítési költség

Értékesítési bruttó nyereség

Kamatköltség a hitelre

EBITDA

Üzemi nyereség

$

Rólunk Relay Therapeutics Inc

Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and Migoprotafib (GDC-1971), an oral, small molecule, potent and selective inhibitor of the protein tyrosine phosphatase SHP2 that binds and stabilizes Src homology region 2 domain-containing phosphatase-2 (SHP2) as a monotherapy in patients with advanced or metastatic solid tumors. In addition, it has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of GDC-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
help-icon Live chat